Leerink Partners reiterates Henry Schein stock rating at $87 target

Henry Schein beat Q4 2025 estimates with EPS $1.34 vs $1.30 and revenue $3.4B vs $3.34B consensus. Leerink Partners reiterated a Market Perform and $87 price target vs the $77.10 stock price (≈13% upside) but says most improvement is priced in; 9 analysts have revised earnings down. Company outgrew the market in equipment/specialty segments and is investing in AI via an AWS partnership, though Leerink remains cautious on dental-market recovery.

Analysis

Henry Schein’s technology investments create a non-obvious vector for margin expansion that the market may not be fully modelling: converting distribution touchpoints into workflow automation and SaaS-like services can trim service and order-processing costs while increasing recurring revenue attachment rates. If AI-driven efficiencies shave 5-8% of field-service / returns-related costs, that mechanically translates into ~100–150 bps gross margin improvement and 50–100 bps operating leverage over 18–36 months, advantaging a broadline distributor vs pure-play OEMs.

Near-term sensitivity is high: revenues tied to elective dental spend mean quarterly prints and equipment order flows will drive sizable price moves in days-to-weeks, while the structural thesis plays out over quarters to years as AI features are adopted. Key reversal triggers are: slower-than-expected clinic reopenings or capex cycles, failure to monetize AWS integrations, or margin pressure from supplier pricing — any of which could unwind forward multiples quickly.

Consensus appears split — some firms price in a normalized dental market but not incremental SaaS adjacencies; conversely, buy-side caution may already cap upside because much of the visible improvement is expected. That creates a clean opportunity to isolate exposures (distribution vs OEM, cyclical spend vs structural software) with paired trades and asymmetric option structures rather than a naked directional bet on the story itself.

Key Decisions for Investors

• Long HSIC equity on weakness: accumulate on intraday dips below $75 (size 1–2% portfolio) with a 9–12 month target of $95 and hard stop at $68. Risk/reward ~3:1 (upside ~27%, downside ~9%) — thesis: capture margin recovery + AI-led recurring revenue lift.
• Pair trade (6–12 months): Long HSIC / Short XRAY equal notional to isolate distribution/recurring-service upside vs OEM cyclical risk. Target spread capture 15–25%; exit if spread narrows by 50% of entry or if HSIC misses 2 consecutive quarters of equipment order growth.
• Defined-risk options hedge / asymmetric upside (12 months): buy HSIC Jan-2027 80C LEAP (or nearest OTM 12-month call) sized to 0.5–1% portfolio risk — payoff if AI monetization + dental recovery accelerate. Alternatively, buy a 6-month 70/60 put spread as insurance against a sharp cyclical downturn (limited premium, defined loss).